NASDAQ:INCR InterCure (INCR) Stock Price, News & Analysis → Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad) Free INCR Stock Alerts $3.28 -0.04 (-1.20%) (As of 10:07 AM ET) Add Compare Share Share Today's Range$3.26▼$3.2850-Day Range$1.75▼$3.6252-Week Range$0.99▼$3.72Volume20,518 shsAverage Volume82,462 shsMarket Capitalization$149.47 millionP/E Ratio25.23Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get InterCure alerts: Email Address Ad Stansberry ResearchThings Are Not Normal in America – Here’s What to DoGet Out of the Dollar Before May 15 A Wall Street legend and our friend has just warned 896,000 Americans to prepare for May 15.This could be your solution. About InterCure Stock (NASDAQ:INCR)InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Read More INCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INCR Stock News HeadlinesMay 2, 2024 | msn.comInterCure Reports Strong FY2023: Performance Paves the Way for Global ExpansionMay 1, 2024 | businesswire.comInterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 millionMay 9, 2024 | Stansberry Research (Ad)Things Are Not Normal in America – Here’s What to DoGet Out of the Dollar Before May 15 A Wall Street legend and our friend has just warned 896,000 Americans to prepare for May 15.April 1, 2024 | msn.comThis Israeli Cannabis Operator Anticipates $95.4M In Revenue Despite Gaza ConflictMarch 22, 2024 | businesswire.comInterCure Congratulates Germany on Cannabis Reform, Expanding its Global FootprintFebruary 23, 2024 | businesswire.comPESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis LandscapeFebruary 13, 2024 | finance.yahoo.comInterCure Provides an Update Regarding Nir Oz FacilityFebruary 13, 2024 | globenewswire.comInterCure Provides an Update Regarding Nir Oz FacilityMay 9, 2024 | Stansberry Research (Ad)Things Are Not Normal in America – Here’s What to DoGet Out of the Dollar Before May 15 A Wall Street legend and our friend has just warned 896,000 Americans to prepare for May 15.January 31, 2024 | msn.comInterCure to buy Isreal-based Leon cannabis pharmacy chainJanuary 18, 2024 | investing.comIntrakat Technikon Kai Energeiakon Ergon AE (INCr)January 10, 2024 | msn.comWKEY, INCR and ZJYL are among pre market gainersJanuary 9, 2024 | benzinga.comIntercure Stock (NASDAQ:INCR) Dividends: History, Yield and DatesJanuary 6, 2024 | investing.comINCR_t3 Historical DataNovember 9, 2023 | morningstar.comIntercure Ltd INCROctober 17, 2023 | msn.comInterCure says one of its sites designated as closed military area by Israeli authoritiesSeptember 1, 2023 | benzinga.comCanndoc Reports Record Revenue Amid Cannabis Market TurmoilAugust 22, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd up on Monday (INCR-U)August 19, 2023 | theglobeandmail.comul: Bottom 25 Performing Stocks Year-to-Date on TSX (INCR-U)August 3, 2023 | msn.comInterCure: Leader In Israel's Growing Medical Cannabis MarketJuly 23, 2023 | theglobeandmail.comIntercure: Top 10 Undervalued Micro Cap Stocks on TSX (INCR-U)July 10, 2023 | financialpost.comInterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASEMay 16, 2023 | finanznachrichten.deInterCure Ltd.: InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOYMay 16, 2023 | msn.comInterCure Stock Trading Lower On Q1 Revenue Growth Of 22%, Here Are The DetailsMay 15, 2023 | benzinga.comInterCure Announces Record Breaking First Quarter Revenues with 22% growth YOYApril 27, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd down on Monday (INCR-U)April 26, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd flat on Monday (INCR-U)See More Headlines Receive INCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InterCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/09/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INCR CUSIPN/A CIK1857030 Webwww.intercure.co Phone972774605012FaxN/AEmployees370Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio25.54 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.23 Current Ratio1.85 Quick Ratio1.38 Sales & Book Value Annual Sales$96.61 million Price / Sales1.57 Cash FlowN/A Price / Cash FlowN/A Book Value$2.72 per share Price / Book1.22Miscellaneous Outstanding Shares45,570,000Free FloatN/AMarket Cap$151.29 million OptionableOptionable Beta1.63 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Alexander Rabinovich (Age 53)CEO & Director Comp: $500kMr. Amos Cohen (Age 45)Chief Financial Officer Comp: $848kEinat ZehaviVice President of SalesMr. Omri BatzirCorporate ControllerKey CompetitorsI-MabNASDAQ:IMABRegulus TherapeuticsNASDAQ:RGLSCervoMedNASDAQ:CRVOAdicet BioNASDAQ:ACETIncannex HealthcareNASDAQ:IXHLView All CompetitorsInstitutional OwnershipMirae Asset Global Investments Co. Ltd.Sold 467,995 shares on 5/1/2024Ownership: 1.477%View All Institutional Transactions INCR Stock Analysis - Frequently Asked Questions How have INCR shares performed in 2024? InterCure's stock was trading at $1.2898 at the beginning of 2024. Since then, INCR stock has increased by 157.4% and is now trading at $3.32. View the best growth stocks for 2024 here. Are investors shorting InterCure? InterCure saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 56,200 shares, a drop of 37.7% from the March 31st total of 90,200 shares. Based on an average daily volume of 90,200 shares, the short-interest ratio is presently 0.6 days. Currently, 0.2% of the shares of the company are short sold. View InterCure's Short Interest. When is InterCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our INCR earnings forecast. Who are InterCure's major shareholders? InterCure's stock is owned by a number of institutional and retail investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (1.48%). How do I buy shares of InterCure? Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INCR) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.